AR051144A1 - Procedimiento para formar atorvastatina amorfa - Google Patents
Procedimiento para formar atorvastatina amorfaInfo
- Publication number
- AR051144A1 AR051144A1 ARP050104486A ARP050104486A AR051144A1 AR 051144 A1 AR051144 A1 AR 051144A1 AR P050104486 A ARP050104486 A AR P050104486A AR P050104486 A ARP050104486 A AR P050104486A AR 051144 A1 AR051144 A1 AR 051144A1
- Authority
- AR
- Argentina
- Prior art keywords
- atorvastatin
- procedure
- solvent
- amorfa
- freeze
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Un procedimiento para formar atorvastatina amorfa que comprende las etapas de disolver atorvastatina en un disolvente no hidroxílico y retirar el disolvente mediante secado por congelacion. Así como procedimiento de disolucion de atorvastatina en un disolvente hidroxílico con un agente solubilizante o un agente alcalinizante o un antioxidante y retirar el disolvente mediante secado por congelacion, liofilizacion de la solucion para producir atorvastatina amorfa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62308604P | 2004-10-28 | 2004-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051144A1 true AR051144A1 (es) | 2006-12-20 |
Family
ID=35954050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104486A AR051144A1 (es) | 2004-10-28 | 2005-10-26 | Procedimiento para formar atorvastatina amorfa |
Country Status (16)
Country | Link |
---|---|
US (4) | US7939675B2 (es) |
EP (1) | EP1807055A1 (es) |
JP (1) | JP2008517992A (es) |
KR (1) | KR20070067175A (es) |
CN (1) | CN101048141A (es) |
AR (1) | AR051144A1 (es) |
AU (1) | AU2005298383A1 (es) |
BR (1) | BRPI0519996A2 (es) |
CA (1) | CA2585836A1 (es) |
IL (1) | IL182474A0 (es) |
MX (1) | MX2007004722A (es) |
NZ (1) | NZ554541A (es) |
RU (1) | RU2007115543A (es) |
TW (1) | TW200624419A (es) |
WO (1) | WO2006046109A1 (es) |
ZA (1) | ZA200702965B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
US20110142883A1 (en) * | 2007-07-20 | 2011-06-16 | Actavis Group Ptc Ehf | Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts |
WO2010066846A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Method for the isolation of atorvastatin |
CN101973922B (zh) * | 2009-05-27 | 2013-01-23 | 天津和美生物技术有限公司 | 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用 |
US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
AU2014277744B2 (en) * | 2010-04-16 | 2017-01-19 | Cumberland Pharmaceuticals, Inc. | Stabilized Statin Formulations |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
CN102139115B (zh) * | 2011-03-30 | 2012-12-05 | 天津红日药业股份有限公司 | 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法 |
EP2760998B1 (en) * | 2011-11-22 | 2017-02-01 | Siemens Healthcare Diagnostics Inc. | Devices containing dried reagents for reconstitution as calibration and/or quality control solutions, and methods of production and use thereof |
EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
MX2020012532A (es) * | 2018-05-31 | 2021-04-28 | Immunity Pharma Ltd | Composiciones y procedimientos de su uso para el tratamiento de esclerosis lateral amiotrofica (ela). |
CN114569605B (zh) * | 2022-03-10 | 2024-08-06 | 沈阳药科大学 | 阿托伐他汀-黄酮类化合物共无定型复合物及其制备方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
WO1994016693A1 (en) * | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
EP1148049B1 (en) * | 1995-07-17 | 2004-12-15 | Warner-Lambert Company | Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
DE69711391T2 (de) * | 1996-07-29 | 2002-11-07 | Warner-Lambert Co., Morris Plains | Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern |
FI106082B (fi) * | 1996-12-05 | 2000-11-15 | Nokia Networks Oy | Menetelmä puhekanavan takaisinkytkemisen havaitsemiseksi sekä puheenkäsittelylaite |
WO1999032434A1 (en) * | 1997-12-19 | 1999-07-01 | Warner-Lambert Export Limited | Process for the synthesis of 1,3-diols |
IN191236B (es) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
AU6253700A (en) | 1999-08-03 | 2001-02-19 | Cottee Dairy Corporation Pty Limited | Packaging |
HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
SI1535613T1 (sl) | 1999-11-17 | 2010-12-31 | Teva Pharma | Postopek za pripravo polimorfne oblike atorvastatin kalcija |
SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
CN1535139A (zh) | 2000-11-03 | 2004-10-06 | ������ҩ��ҵ����˾ | 阿伐他丁半钙形式ⅶ |
JP4234429B2 (ja) | 2000-11-16 | 2009-03-04 | テバ ファーマシューティカル インダストリーズ リミティド | 水酸化カルシウムによる〔R(R*,R*)〕−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−〔(フェニルアミノ)カルボニル〕−1H−ピロール−1−ヘプタン酸エステルの加水分解 |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
EP1345896B1 (en) | 2000-12-27 | 2009-01-07 | Teva Pharmaceutical Industries Limited | Crystalline forms of atorvastatin |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
IN190564B (es) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
EA005317B1 (ru) * | 2001-06-29 | 2004-12-30 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1h-пиррол-1-гептановой кислоты кальциевой соли (2:1) (аторвастатин) |
US6598010B2 (en) | 2001-07-11 | 2003-07-22 | Uri Zefira | Method for achieving accurate measurement of true weight |
JP2005500351A (ja) | 2001-07-30 | 2005-01-06 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 結晶形態viおよびviiのアトルバスタチンカルシウム |
UA77990C2 (en) | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
PL371337A1 (en) * | 2002-02-14 | 2005-06-13 | Ranbaxy Laboratories Limited | Formulations of atorvastatin stabilized with alkali metal additions |
US7230120B2 (en) * | 2002-03-18 | 2007-06-12 | Biocon | Amorphous HMG-CoA reductase inhibitors of desired particle size |
EP1562583A1 (en) | 2002-09-03 | 2005-08-17 | Morepen Laboratories Ltd. | Atorvastatin calcium form vi or hydrates thereof |
-
2005
- 2005-10-12 AU AU2005298383A patent/AU2005298383A1/en not_active Abandoned
- 2005-10-12 RU RU2007115543/15A patent/RU2007115543A/ru not_active Application Discontinuation
- 2005-10-12 CA CA002585836A patent/CA2585836A1/en not_active Abandoned
- 2005-10-12 EP EP05796593A patent/EP1807055A1/en not_active Withdrawn
- 2005-10-12 CN CNA2005800372855A patent/CN101048141A/zh active Pending
- 2005-10-12 JP JP2007538529A patent/JP2008517992A/ja not_active Withdrawn
- 2005-10-12 US US11/666,707 patent/US7939675B2/en active Active
- 2005-10-12 NZ NZ554541A patent/NZ554541A/en unknown
- 2005-10-12 BR BRPI0519996-4A patent/BRPI0519996A2/pt not_active IP Right Cessation
- 2005-10-12 MX MX2007004722A patent/MX2007004722A/es not_active Application Discontinuation
- 2005-10-12 KR KR1020077009632A patent/KR20070067175A/ko not_active Application Discontinuation
- 2005-10-12 WO PCT/IB2005/003173 patent/WO2006046109A1/en active Application Filing
- 2005-10-26 AR ARP050104486A patent/AR051144A1/es not_active Application Discontinuation
- 2005-10-27 TW TW094137646A patent/TW200624419A/zh unknown
-
2007
- 2007-04-11 IL IL182474A patent/IL182474A0/en unknown
- 2007-04-11 ZA ZA200702965A patent/ZA200702965B/xx unknown
-
2011
- 2011-04-04 US US13/079,376 patent/US8258315B2/en active Active
-
2012
- 2012-07-27 US US13/559,776 patent/US8686163B2/en active Active
-
2014
- 2014-02-08 US US14/176,081 patent/US9056831B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
NZ554541A (en) | 2011-01-28 |
US20120289576A1 (en) | 2012-11-15 |
US20080269314A1 (en) | 2008-10-30 |
US20110237642A1 (en) | 2011-09-29 |
WO2006046109A1 (en) | 2006-05-04 |
US9056831B2 (en) | 2015-06-16 |
EP1807055A1 (en) | 2007-07-18 |
US7939675B2 (en) | 2011-05-10 |
CA2585836A1 (en) | 2006-05-04 |
MX2007004722A (es) | 2007-06-15 |
RU2007115543A (ru) | 2008-12-10 |
ZA200702965B (en) | 2008-10-29 |
JP2008517992A (ja) | 2008-05-29 |
US20140155627A1 (en) | 2014-06-05 |
US8686163B2 (en) | 2014-04-01 |
US8258315B2 (en) | 2012-09-04 |
IL182474A0 (en) | 2007-07-24 |
CN101048141A (zh) | 2007-10-03 |
AU2005298383A1 (en) | 2006-05-04 |
KR20070067175A (ko) | 2007-06-27 |
BRPI0519996A2 (pt) | 2009-04-07 |
TW200624419A (en) | 2006-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051144A1 (es) | Procedimiento para formar atorvastatina amorfa | |
AR050717A1 (es) | Composiciones farmaceuticas | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
CL2008001124A1 (es) | Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
EA200702550A1 (ru) | Способ получения эпоксида | |
BRPI0915439B8 (pt) | composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição | |
UY28862A1 (es) | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
CL2008002076A1 (es) | Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades. | |
CL2008003265A1 (es) | Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores. | |
CL2008002394A1 (es) | Depsipeptido ciclico, o derivados, inhibidores de calicreína 7, obtenidos desde chondromyces crocatus, metodo de obtencion y usos terapeuticos. | |
CL2004000807A1 (es) | Composicion de extraccion por solvente que comprende una o mas ortohidroxiarilaldoxinas y una o mas ortohidroxiarilcetoxinas y uno o mas modificadores de equilibrio para producir un grado de modificacion de las ortohidroxialrilaldoximas, de aproximad | |
BR112015001655A2 (pt) | método para purificar pelo menos uma saponina em uma solução, componente de produto de saponina qs-21 purificada, e, composição imunogênica | |
AR077372A1 (es) | Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales | |
CL2011000341A1 (es) | Compuestos derivados de pirrolidinona sustituida, moduladores de la actividad de ar para la inhibicion de ntd; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de cancer, acne, hirsutismo, entre otras. | |
AR044659A1 (es) | Procedimiento para la formacion de atorvastatina amorfa | |
GT201000175A (es) | Uso de derivados de ácido tetrámico para controlar nematodos | |
CL2007003859A1 (es) | Metodo para eliminar arsenico que comprende contactar la solucion con un agente precipitante de tierra rara para precipitar arsenico y obtener solucion parcialmente liberada de arsenico y agente cargado con arsenico,contactar la solucion separada con una segunda porcion de agente precipitante;y aparato para separar arsenico. | |
PA8597501A1 (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
AR048672A1 (es) | Tabletas de desintegracion que comprenden licarbazepina | |
GT200800066A (es) | Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento. | |
UY29631A1 (es) | Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica | |
CL2011002651A1 (es) | Composicion veterinaria que comprende dipropionato de imidocarb, cianocobalamina vitamina b12 y un vehiculo farmaceuticamente aceptable; y su uso para tratar o prevenir enfermedades infecciosas parasitarias en ganado. | |
CL2008001766A1 (es) | Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis. | |
AR048756A1 (es) | Procedimiento para formar atorvastatina amorfa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |